Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:FEMY NASDAQ:MBOT NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.28+9.1%$1.83$0.76▼$2.73$78.99M1.3185,785 shs52,823 shsFEMYFemasys$0.94+2.2%$0.95$0.69▼$1.80$29.81M-2.56265,152 shs141,543 shsMBOTMicrobot Medical$2.52-1.2%$2.56$0.82▼$3.38$92.76M1.131.81 million shs1.37 million shsSLNOSoleno Therapeutics$87.64+2.5%$79.38$41.50▼$90.32$4.31B-2.63849,838 shs1.71 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+1.95%-8.33%+12.37%+111.11%+51.45%FEMYFemasys-1.34%-5.15%+1.10%-25.81%-23.33%MBOTMicrobot Medical+2.82%+2.00%+4.08%+2.41%+132.88%SLNOSoleno Therapeutics+2.31%-3.36%+9.43%+22.21%+65.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.2014 of 5 stars0.04.00.04.22.71.70.6FEMYFemasys2.8653 of 5 stars3.53.00.00.02.22.50.6MBOTMicrobot Medical2.2721 of 5 stars3.53.00.00.02.70.00.6SLNOSoleno Therapeutics4.5869 of 5 stars4.51.00.04.62.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/AFEMYFemasys 3.00Buy$8.67825.14% UpsideMBOTMicrobot Medical 3.00Buy$9.00257.14% UpsideSLNOSoleno Therapeutics 3.09Buy$108.7024.03% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, SLNO, MBOT, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$105.00 ➝ $121.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.004/24/2025SLNOSoleno TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $145.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.79N/AN/A$0.38 per share6.00FEMYFemasys$1.63M18.70N/AN/A$0.10 per share9.37MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.550.00N/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)FEMYFemasys-$18.82M-$0.910.00N/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.650.00N/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.620.00N/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest FEMY, SLNO, MBOT, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AFEMYFemasys-$0.18N/AN/AN/AN/AN/A8/13/2025N/AMBOTMicrobot Medical-$0.08N/AN/AN/AN/AN/A8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64FEMYFemasys0.020.930.54MBOTMicrobot MedicalN/A16.1916.19SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%FEMYFemasys65.27%MBOTMicrobot Medical16.30%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%FEMYFemasys11.54%MBOTMicrobot Medical4.74%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million32.05 millionOptionableFEMYFemasys3032.53 million28.77 millionNot OptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableFEMY, SLNO, MBOT, and APYX HeadlinesRecent News About These CompaniesSoleno Therapeutics: Fairly Valued Despite M&A ExpectationsJuly 16 at 3:15 AM | seekingalpha.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by TimesSquare Capital Management LLCJuly 15 at 6:32 AM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $121.00 at Robert W. BairdJuly 14 at 2:31 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Advisers LLC's 8th Largest PositionJuly 13, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Mutual Fund Advisers Trust's 7th Largest PositionJuly 12, 2025 | marketbeat.comSoleno Therapeutics Shares Dip Following $200 Million Stock Offering PricingJuly 11, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJuly 11, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume - Time to Buy?July 10, 2025 | marketbeat.comSoleno Therapeutics stock dips on proposed $200M offeringJuly 10, 2025 | msn.comSoleno Therapeutics Announces Pricing of $200 Million Public Offering of Common StockJuly 10, 2025 | globenewswire.comSoleno Therapeutics, Inc. Announces $200 Million Public Offering to Fund VYKAT XR Commercialization and R&D ActivitiesJuly 10, 2025 | quiverquant.comQSoleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XRJuly 10, 2025 | quiverquant.comQSoleno Therapeutics Announces Proposed $200 Million Public Offering of Common StockJuly 10, 2025 | globenewswire.comSoleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025July 10, 2025 | globenewswire.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 52-Week High - Time to Buy?July 9, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of "Buy" from AnalystsJuly 9, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Recommendation of "Buy" by BrokeragesJuly 9, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Lowered by Allspring Global Investments Holdings LLCJuly 6, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $316,970.80 in StockJuly 4, 2025 | insidertrades.comOppenheimer & Co. Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 4, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Patricia C. Hirano Sells 3,830 SharesJuly 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, SLNO, MBOT, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$2.28 +0.19 (+9.09%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.18 (+7.72%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Femasys NASDAQ:FEMY$0.94 +0.02 (+2.23%) Closing price 04:00 PM EasternExtended Trading$0.94 0.00 (-0.19%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Microbot Medical NASDAQ:MBOT$2.52 -0.03 (-1.18%) Closing price 04:00 PM EasternExtended Trading$2.54 +0.02 (+0.79%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Soleno Therapeutics NASDAQ:SLNO$87.64 +2.12 (+2.48%) Closing price 04:00 PM EasternExtended Trading$87.68 +0.03 (+0.04%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
